REGENXBIO Toekomstige groei
Future criteriumcontroles 2/6
De verwachting is dat REGENXBIO de winst en omzet met respectievelijk 33% en 36.3% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 40.9% per jaar.
Belangrijke informatie
33.0%
Groei van de winst
40.9%
Groei van de winst per aandeel
Biotechs winstgroei | 28.3% |
Inkomstengroei | 36.3% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 21 Nov 2024 |
Recente toekomstige groei-updates
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11Recent updates
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Oct 31Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Sep 12Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Aug 06REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 202 | -158 | -146 | N/A | 7 |
12/31/2025 | 310 | -32 | 153 | N/A | 11 |
12/31/2024 | 87 | -240 | -178 | N/A | 11 |
9/30/2024 | 84 | -239 | -185 | -182 | N/A |
6/30/2024 | 89 | -241 | -195 | -191 | N/A |
3/31/2024 | 87 | -260 | -199 | -193 | N/A |
12/31/2023 | 90 | -263 | -228 | -218 | N/A |
9/30/2023 | 99 | -261 | -231 | -217 | N/A |
6/30/2023 | 97 | -274 | -236 | -218 | N/A |
3/31/2023 | 110 | -270 | -257 | -232 | N/A |
12/31/2022 | 113 | -280 | -238 | -207 | N/A |
9/30/2022 | 480 | 74 | 134 | 173 | N/A |
6/30/2022 | 484 | 91 | 128 | 181 | N/A |
3/31/2022 | 474 | 101 | 143 | 207 | N/A |
12/31/2021 | 470 | 128 | 135 | 219 | N/A |
9/30/2021 | 93 | -212 | -166 | -83 | N/A |
6/30/2021 | 161 | -145 | -147 | -77 | N/A |
3/31/2021 | 156 | -121 | -116 | -63 | N/A |
12/31/2020 | 155 | -111 | -81 | -54 | N/A |
9/30/2020 | 145 | -91 | -134 | -119 | N/A |
6/30/2020 | 61 | -135 | -123 | -112 | N/A |
3/31/2020 | 52 | -103 | -128 | -114 | N/A |
12/31/2019 | 35 | -95 | -119 | -108 | N/A |
9/30/2019 | 64 | -64 | -102 | -86 | N/A |
6/30/2019 | 55 | -49 | -93 | -77 | N/A |
3/31/2019 | 87 | -37 | 4 | 17 | N/A |
12/31/2018 | 219 | 100 | 91 | 105 | N/A |
9/30/2018 | 180 | 80 | 84 | 95 | N/A |
6/30/2018 | 176 | 78 | N/A | 97 | N/A |
3/31/2018 | 142 | 53 | N/A | 18 | N/A |
12/31/2017 | 10 | -73 | N/A | -58 | N/A |
9/30/2017 | 10 | -77 | N/A | -65 | N/A |
6/30/2017 | 9 | -74 | N/A | -59 | N/A |
3/31/2017 | 5 | -74 | N/A | -58 | N/A |
12/31/2016 | 5 | -63 | N/A | -49 | N/A |
9/30/2016 | 7 | -49 | N/A | -33 | N/A |
6/30/2016 | 8 | -38 | N/A | -29 | N/A |
3/31/2016 | 7 | -32 | N/A | -29 | N/A |
12/31/2015 | 8 | -24 | N/A | -23 | N/A |
9/30/2015 | 4 | -21 | N/A | -18 | N/A |
6/30/2015 | 4 | -16 | N/A | -13 | N/A |
3/31/2015 | 4 | -8 | N/A | -5 | N/A |
12/31/2014 | 6 | -5 | N/A | -2 | N/A |
12/31/2013 | 6 | -6 | N/A | -3 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat RGNX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat RGNX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat RGNX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van RGNX ( 36.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van RGNX ( 36.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van RGNX naar verwachting over 3 jaar hoog zal zijn